Survodutide

Development and Design

Survodutide (development code BI 456906) is an investigational dual agonist of the GLP-1 and glucagon receptors, developed jointly by Boehringer Ingelheim and Zealand Pharma. It is a lipidated synthetic peptide built for once-weekly subcutaneous dosing, using an albumin-binding fatty-acid side chain analogous to the pharmacokinetic architecture of semaglutide.

Unlike tirzepatide (GLP-1/GIP) or retatrutide (GLP-1/GIP/glucagon), survodutide pairs GLP-1 agonism with glucagon receptor activation without GIP. The design rationale is that glucagon agonism drives hepatic fatty-acid oxidation and raises energy expenditure, while concurrent GLP-1 agonism controls blood glucose and suppresses appetite — together producing weight loss and, importantly, direct hepatic effects that make the compound particularly interesting in metabolic liver disease.

Mechanism — The Liver-Centric Thesis

The metabolic signature of dual GLP-1/glucagon agonism differs from pure GLP-1 or dual GLP-1/GIP therapy in several ways:

• Direct hepatic lipid mobilization. Glucagon receptors are highly expressed on hepatocytes; activation drives fatty-acid oxidation and reduces hepatic triglyceride storage, making glucagon co-agonism particularly relevant for steatotic liver disease.
• Increased resting energy expenditure. Small but measurable rises in thermogenesis contribute to weight loss beyond appetite suppression alone.
• Balanced glucose effects. Glucagon's hyperglycemic effect is offset by GLP-1-driven insulinotropic response, such that net glycemic effect is favorable.

Clinical Evidence

Survodutide's Phase 2 obesity trial, published in 2024, reported mean weight loss of approximately 18.7% at 46 weeks on the highest dose in adults with obesity — a magnitude competitive with tirzepatide and approaching but not matching early retatrutide Phase 2 data. Phase 2 work in type 2 diabetes showed meaningful HbA1c reductions, though survodutide's strategic positioning has focused increasingly on indications beyond T2D.

The most consequential development for survodutide is its MASH (metabolic dysfunction-associated steatohepatitis) program. A Phase 2 MASH trial reported in 2024 that survodutide produced MASH resolution without fibrosis worsening in a substantially higher proportion of patients than placebo, with additional benefit on fibrosis improvement itself — the first large signal for a GLP-1/glucagon co-agonist specifically on hepatic histology endpoints. Boehringer Ingelheim advanced survodutide into Phase 3 in MASH under the LIVERAGE program, alongside parallel Phase 3 trials in obesity.

Competitive Position

Survodutide occupies an interesting strategic niche. In pure weight loss, it faces tough competition from tirzepatide (approved and established) and retatrutide (likely to read out Phase 3 efficacy on similar timelines). Its defensible wedge is MASH — where it has the strongest GLP-1-class histology data to date, arriving into a category where Madrigal's resmetirom (Rezdiffra) became the first FDA-approved MASH therapy in March 2024 but where the market is far from consolidated.

Phase 3 readouts for survodutide in both obesity and MASH are expected through 2026 and 2027, with potential regulatory filings depending on the pace of enrollment and interim analysis.

Safety Signals

Phase 2 tolerability has been broadly consistent with the GLP-1 class — gastrointestinal symptoms dominant, concentrated during titration. Modest heart-rate elevation and small increases in hepatic transaminases were reported, the latter being an area of close Phase 3 scrutiny given the MASH target indication. No novel safety signals distinct from the broader GLP-1-class experience have emerged publicly.

The Bottom Line

Survodutide is the most clinically advanced dual GLP-1/glucagon co-agonist and the strongest candidate in that particular receptor-pair category. Its likeliest path to regulatory success is in MASH, where the histology-endpoint data from Phase 2 is genuinely differentiating. In the obesity market it will be a second-line multi-agonist competing with already-approved tirzepatide and, potentially, soon-approved retatrutide. For the full multi-agonist landscape, see our 2026 GLP-1 class comparison.